Company profile

Omeros Corporation

Pipeline4 assets

NarsoplimabOMS721 / Yartemlea / MASP-2 / Monoclonal antibody / Hematology / Complement-Mediated Diseases
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
ZaltenibartOMS906 / MASP-3 / Monoclonal antibody / Hematology / Nephrology
Paroxysmal nocturnal hemoglobinuria (PNH)C3 glomerulopathy
OMS1029OMS1029 / MASP-2 / Biologic / Complement-Mediated Diseases
OMS527OMS527 / PDE7 / Small molecule / Addiction
Cocaine use disorder

Latest news11 items

May 13, 2026

Omeros Corporation Reports First Quarter 2026 Financial Results

May 11, 2026

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Apr 16, 2026

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Mar 31, 2026

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 26, 2026

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 21, 2026

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Feb 17, 2026

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Jan 27, 2026

Omeros Announces First Commercial Sales of YARTEMLEA®

Dec 26, 2025

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 24, 2025

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 1, 2025

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation • Endpoint Arena